

Cefalexin (Cephalexin)

For newborn use only

2019

Alert	The Antimicrobial Stewardship Team recommends this drug is listed under the following category: Unrestricted.														
Indication	Treatment of mild infections due to susceptible strains of bacteria. Prophylaxis of urinary tract infections in patients at risk (e.g. vesicoureteric reflux).														
Action	First generation cephalosporin. Bactericidal – inhibits cell wall synthesis in susceptible organisms. Most active against Gram-positive cocci, including MSSA and streptococci. Has no activity against enterococci, MRSA or <i>Listeria</i> . ¹														
Drug Type	Cephalosporin antibiotic.														
Trade Name	APO-Cephalexin, Cefalexin Sandoz, Ialex, Ibilex, Keflex.														
Presentation	125 mg/5 mL suspension 250 mg/5mL suspension														
Dosage / Interval	<p>Treatment</p> <table border="1"> <thead> <tr> <th colspan="2">Method</th> <th rowspan="2">Interval</th> </tr> <tr> <th>Postnatal Age (Days)</th> <th>Dose</th> </tr> </thead> <tbody> <tr> <td>0–7 days</td> <td>25 mg/kg</td> <td>12-hourly</td> </tr> <tr> <td>8–28 days</td> <td>25 mg/kg</td> <td>8-hourly</td> </tr> <tr> <td>29+ days</td> <td>25 mg/kg</td> <td>6-hourly</td> </tr> </tbody> </table> <p>Prophylaxis of urinary tract infection (UTI) 12.5 (10–15) mg/kg/dose DAILY (maximum dose 125 mg daily).^{7,8}</p> <p>Prophylaxis around Voiding Cystourethrogram 12.5 (10–15) mg/kg/dose 8-hourly for 3 days (day prior, on the day and one day after MCU).¹⁰</p>	Method		Interval	Postnatal Age (Days)	Dose	0–7 days	25 mg/kg	12-hourly	8–28 days	25 mg/kg	8-hourly	29+ days	25 mg/kg	6-hourly
Method		Interval													
Postnatal Age (Days)	Dose														
0–7 days	25 mg/kg	12-hourly													
8–28 days	25 mg/kg	8-hourly													
29+ days	25 mg/kg	6-hourly													
Route	Oral														
Maximum Daily Dose	500 mg														
Preparation/Dilution	Powder usually reconstituted by Pharmacy. If supplied unreconstituted, reconstitute powder for oral suspension using water for injection with the volume specified on the bottle.														
Administration	Oral: Prophylactic dose: May be taken with or without food. Treatment dose: Preferably commence treatment without feeds (faster absorption and higher peak concentrations) ³ Shake bottle well before measuring dose.														
Monitoring	Monitor renal, hepatic and haematological function with prolonged use.														
Contraindications	Hypersensitivity to cephalosporins. Immediate hypersensitivity or severe reaction to penicillins.														
Precautions	Use with caution in patients with hypersensitivity or mild adverse reactions to penicillins or carbapenems as cross-reactivity can occur (e.g. rash).														
Drug Interactions	Nil relevant.														
Adverse Reactions	Diarrhoea, dyspepsia, abdominal pain, nausea and vomiting. Pseudomembranous colitis (rare). Transient elevation of liver enzymes. Hypersensitivity: Immediate – urticaria, bronchospasm, anaphylaxis. Delayed – maculopapular rash, fever, eosinophilia.														
Compatibility	Can be given with food.														
Incompatibility	Not applicable.														
Stability	Reconstituted solution should be discarded after 14 days.														
Storage	Store powder below 25°C Store reconstituted solution between 2 and 8°C														
Special Comments	May cause false positive Coombs test. Consider increasing dosing interval in significant renal impairment.														
Evidence summary	Refer to full version.														

Cefalexin (Cephalexin)

For newborn use only

2019

References	Refer to full version.
------------	------------------------

Original version Date: 08/08/2015	Author: ANMF Consensus Group
Previous Version number: 1.1	Previous Version Date: 25/11/2016
Current version Number: 2.0	Current version date: 20/05/2019
Risk Rating: Low	Due for Review: 20/05/2024
Approval by: As per Local policy	Approval Date: As per Local policy

Authors Contribution

Original author/s	Chris Wake
Author/s of the current review	Srinivas Bolisetty
Evidence Review - original	David Osborn
Expert review	Brendan McMullan, Sean Kennedy, Anne Durkan
Nursing Review	Eszter Jozsa
Pharmacy Review	Jing Xiao, Michelle Jenkins, Cindy Chen
ANMF Group contributors	Nilkant Phad, Himanshu Popat
Final editing and review of the original	Ian Whyte
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty